Tyrosine Kinase Inhibitors BCL Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy MDM2/MDMX Other Serine-Threonine Kinase Inhibitors Chemotherapy DNA Epigenetics Cyclin Dependent Kinase Inhibitors Interleukins | Acute Myelogenous Leukemia | Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia |
---|---|---|---|---|
ruxolitinib | ||||
venetoclax | ||||
cytarabine + cladribine | ||||
pembrolizumab | ||||
venetoclax + RG7388 | ||||
decitabine + cladribine | ||||
BTX-A51 | ||||
sintilimab | ||||
venetoclax + decitabine/cedazuridine | ||||
HAG + azacitidine | ||||
gemtuzumab ozogamicin | ||||
azacitidine | ||||
cytarabine + clofarabine | ||||
decitabine + clofarabine | ||||
cytarabine/daunorubicin liposomal formulation | ||||
cytarabine | ||||
tagraxofusp-erzs | ||||
CDIAG | ||||
LY3009120 | ||||
Tyrosine kinase inhibitor |